Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 1,748 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cardiovascular Risks Clear all

Conditions: Systemic Lupus Erythematosus
Interventions: Dehydroepiandrosterone (DHEA); Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Ventricular Tachycardia, Cardiovascular Diseases, Arrythmia, CVD
Interventions: Not listed
Lead sponsor: CardioDx; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Ischemic Stroke, Transient Ischemic Attack
Interventions: Physician stroke guideline adherence, Stroke Self Management, Attention Control Group; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Indianapolis, Indiana • Houston, Texas

Conditions: Carotid Artery Disease, Carotid Stenosis, Stroke, Atherosclerosis
Interventions: Carotid artery stenting with filter (interventional), Carotid artery endarterectomy (surgical); Device · Procedure
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 1,663 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 62
States / cities: Phoenix, Arizona • Mountain View, California • Newport Beach, California + 52 more

Conditions: Atherosclerosis, High Blood Pressure, Type 2 Diabetes Mellitus, Heart Disease, Hypercholesterolemia
Interventions: Special Intervention; Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 40 Years and older
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Physical Activity
Interventions: MAGIC, Control; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 5 Years and older
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV-1-infection, Elevated Cardiovascular Risk
Interventions: CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 45 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 19
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 14 more

Conditions: Cardiovascular Risk, Chronic Kidney Disease, Inflammation
Interventions: Ziltivekimab B, Ziltivekimab C, Placebo (Ziltivekimab B), Placebo (Ziltivekimab C); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 6,385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 181
States / cities: Birmingham, Alabama • Montgomery, Alabama • Glendale, Arizona + 140 more

Conditions: Health Behavior
Interventions: SomaSignal Test Results; Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 40 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Head and Neck Cancer, Carotid Artery Stenosis, Cardiovascular Complication
Interventions: Carotid ultrasound, Blood draw, Survey; Procedure · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Sudden Cardiac Death
Interventions: Electrophysiology study (EPS), Standard Care, Cardiac Magnetic Resonance (CMR); Procedure · Other
Lead sponsor: Western Sydney Local Health District; Other
Eligibility: 18 Years to 85 Years
Enrollment: 1,058 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity
Interventions: recombinant human growth hormone (rhGH), Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 13 Years to 21 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: Dietary and physical activity JITAI delivered through the myBPmyLife app, Control Group; Behavioral · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Flint, Michigan

Conditions: Cardiovascular Disease, HIV
Interventions: Telephone, Educational pamphlets; Behavioral · Other
Lead sponsor: Duke University; Other
Eligibility: 40 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypertension
Interventions: E3 Remote Monitoring and Social Intervention; Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cardioprotection
Interventions: Chocolate; Other
Lead sponsor: Griffin Hospital; Other
Eligibility: 30 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Derby, Connecticut

Conditions: Prostate Cancer, Cardiovascular Disease
Interventions: Nutrition, Exercise, Smoking cessation, Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin), ACE inhibitor; Behavioral · Drug
Lead sponsor: McMaster University; Other
Eligibility: 45 Years and older · Male only
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 4
States / cities: Augusta, Georgia • Kansas City, Kansas • Philadelphia, Pennsylvania + 1 more

Conditions: Acute Coronary Syndrome
Interventions: Behavioral Activation for Health and Depression (BA-HD), Enhanced Usual Care; Behavioral · Other
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Greenville, North Carolina • Providence, Rhode Island

Conditions: Major Depressive Disorder, Cardiovascular Diseases, Inflammation, Blood Pressure, Heart Rate Variability
Interventions: Single-session emotion regulation training; Behavioral
Lead sponsor: University of Southern Mississippi; Other
Eligibility: 18 Years to 29 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Hattiesburg, Mississippi

Conditions: Preeclampsia, Pregnancy Induced Hypertension
Interventions: Irbesartan; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 50 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: High potassium dietary education/counseling, Low sodium dietary education/counseling; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Knee Osteoarthritis
Interventions: Hylan G-F 20, Control; Device · Other
Lead sponsor: OhioHealth; Other
Eligibility: 40 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Interventions: Epanova® (omega-3 carboxylic acids), corn oil control; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 13,078 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 229
States / cities: Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 183 more

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, Lymphoproliferative Disorder, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent High Risk Myelodysplastic Syndrome, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide, Fludarabine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Pharmacological Study, Tacrolimus, Thiotepa; Procedure · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years to 75 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention

Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial

Adapting Tools to Implement Stroke Risk Management to Veterans

Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)

Latinos Understanding the Need for Adherence

Evaluating an Implementation Strategy to Improve Physical Activity and Reduce Cardiovascular Risk Factors in Children

A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

Evaluating the Impact of SomaSignal Tests on Medical Management and Change in Risk in Patients at Higher Risk of Cardiovascular Disease: A Feasibility and an Adaptive Implementation Study

Carotid Ultrasound to Identify Head and Neck Cancer Survivors With High Cardiovascular Risk After Radiation Therapy

Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)

Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls

Improving Blood Pressure Control Through the myBPmyLife mHealth Application

Case Managers for CVD Risk Reduction in HIV Clinic

Novartis - Closing the Gap in Cardiovascular Risk: Engage, Empower, Evaluate

Cocoa and Endothelial Function in Adults With Elevated BMI

A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

Healthy Heart Habits-2

Emotion Regulation Training to Reduce Cardiovascular Disease Risk Among Depressed Young Adults in Southern Mississippi

Preeclampsia: A Marker for Future Cardiovascular Risk in Women

Sodium vs Potassium Education to Improve Vascular Health

Pilot Study of Therapy With Hylan G-F 20 Exercise Capacity

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant